Shifting paradigms of surgical management in advanced ovarian cancer: Organ specific surgical assessments

Anatomic fingerprints for cytoreduction in advanced ovarian cancer - ANAFI study; anatomic fingerprints for cytoreduction in advanced ovarian cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049480

Enrollment

800

Registered

2022-11-14

Start date

2018-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with an advanced stage of epithelial ovarian cancer who are eligible for surgical cytoreductive treatment

Exclusion criteria

Exclusion criteria: Patients with recurrent ovarian cancer Patients with a synchronous primary tumour Patients with non-epithelial ovarian cancer Patient with comorbidities that makes them ineligible for cytoreductive surgery

Design outcomes

Primary

Measure	Time frame
Complete surgical cytoreduction rates measures as residual disease according to Sugarbaker criteria	—

Secondary

Measure	Time frame
Overall survival, progression-free survival, sentitivity, specificity, and post-operative morbidity according to Clavien-Dindo	—

Countries

Europe

Contacts

Public ContactAlexandros Laios

St. James's University Hospital LTHT Department of Gynaecological Oncology

a.laios@nhs.net+44(0)1132068251

Outcome results